Pleural Effusion Identified
CXR or CT shows pleural fluid collection
All Pathways
Pulmonary MedicineDiagnostic
Pleural Effusion Diagnostic and Management Algorithm (BTS 2023)
Pleural Effusion Diagnostic and Management Algorithm (BTS 2023): Pleural Effusion Identified → Clinical Assessment → Obvious Transudative Cause? → Treat...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Action Clinical Assessment
History and examination
- Symptoms: dyspnea, pleuritic pain, cough
- Duration and progression
- History: HF, liver disease, malignancy, infection
- Medications: drugs causing effusion
- Physical exam: dullness, decreased breath sounds
03Decision Obvious Transudative Cause?
Clinical diagnosis sufficient?
- Bilateral effusions with heart failure
- Known cirrhosis with ascites
- Nephrotic syndrome
- Typical clinical picture
04Action Treat Underlying Cause
No diagnostic tap needed initially
- Optimize heart failure treatment
- Diuretics for transudate
- Monitor response
- Tap if no response or atypical features
05Action Diagnostic Thoracentesis
Ultrasound-guided aspiration
- USS guidance mandatory (BTS 2023)
- Aspirate 20-50mL for diagnosis
- Send: pH, protein, LDH, glucose, cytology, culture
- Consider: Amylase, cholesterol, triglycerides, ADA
06Decision Apply Light's Criteria
Exudate if ANY met
- Pleural protein/serum protein >0.5
- Pleural LDH/serum LDH >0.6
- Pleural LDH >2/3 upper limit normal
- EXUDATE if any positive
07Action Transudate
Usually cardiac, hepatic, or renal cause
- Common: Heart failure, cirrhosis, nephrotic
- Less common: Hypothyroidism, PE, constrictive pericarditis
- Treat underlying condition
- Therapeutic tap if symptomatic
08Outcome Discharge & Follow-up
Plan based on etiology
- Repeat CXR in 4-6 weeks if resolving
- Outpatient follow-up for ongoing management
- Respiratory referral for complex cases
09Decision Exudate - Further Workup
Determine etiology
- Infection (parapneumonic, empyema, TB)
- Malignancy
- Inflammatory (RA, SLE)
- PE, pancreatitis, drugs
10Decision Infection Markers?
pH, glucose, appearance
- pH <7.2 = Complicated parapneumonic/empyema
- Glucose <40 mg/dL = Complicated effusion
- Pus = Empyema
- Positive Gram stain/culture
11Warning Complicated Parapneumonic/Empyema
Requires drainage
- Chest drain insertion
- Small bore (10-14Fr) often adequate
- IV antibiotics
- Consider intrapleural fibrinolytics (tPA/DNase)
- Surgical referral if not improving
- Path rejoins step 08Shared downstream outcome
12Action Simple Parapneumonic
Antibiotics, monitor
- pH >7.2, glucose normal
- Antibiotics alone usually sufficient
- Repeat imaging in 48-72h
- Tap if enlarging or not improving
- Path rejoins step 08Shared downstream outcome
13Decision Cytology/Other Tests
For non-infectious exudate
- Cytology positive = Malignant
- High ADA = TB consideration
- Chylothorax: Triglycerides >110
- Amylase elevated = Pancreatic/esophageal
14Action Malignant Pleural Effusion
Palliative management focus
- Symptom relief priority
- Options: Repeat aspiration, IPC, pleurodesis
- Indwelling pleural catheter (IPC) increasingly used
- Talc pleurodesis if good performance status
- Involve palliative care
- Path rejoins step 08Shared downstream outcome
15Action Undiagnosed Effusion
Consider further investigation
- CT thorax with contrast
- Repeat thoracentesis
- Thoracoscopy (VATS or medical)
- Pleural biopsy if TB suspected
- PET-CT for occult malignancy
- Path rejoins step 08Shared downstream outcome
- Path rejoins step 05Shared downstream outcome
Guideline Source
British Thoracic Society Guideline for Pleural Disease 2023
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not cover pediatric pleural effusion
- Malignant effusion management simplified
- Empyema staging requires clinical judgment
- Light's criteria have known limitations
Contraindicated Populations
pediatric
Applicable Regions
UKEUGlobal
Global: Light's criteria universally applicable; local resources may vary
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Pulmonary Embolism Severity Index (PESI)
30-day mortality risk stratification for acute pulmonary embolism
Open page
Compare
AttendMe.ai vs DynaMed
See how this pathway workflow compares against DynaMed.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Pleural Effusion Diagnostic and Management Algorithm (BTS 2023)?
The Pleural Effusion Diagnostic and Management Algorithm (BTS 2023) is a diagnostic clinical algorithm for Pulmonary Medicine. It provides a structured decision tree to guide clinical decision-making, based on British Thoracic Society Guideline for Pleural Disease 2023.
What guideline is the Pleural Effusion Diagnostic and Management Algorithm (BTS 2023) based on?
This algorithm is based on British Thoracic Society Guideline for Pleural Disease 2023 (DOI: 10.1136/thorax-2023-220304).
What are the limitations of the Pleural Effusion Diagnostic and Management Algorithm (BTS 2023)?
Known limitations include: Does not cover pediatric pleural effusion; Malignant effusion management simplified; Empyema staging requires clinical judgment; Light's criteria have known limitations. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Pleural Effusion Diagnostic and Management Algorithm (BTS 2023) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free